Year All 2026 2025 2024 2023 September 1, 2026 Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference August 10, 2026 Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance August 10, 2026 Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures July 28, 2026 Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome July 14, 2026 Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026 July 13, 2026 Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases July 10, 2026 Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling July 7, 2026 Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research June 2, 2026 Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics May 8, 2026 Alamar Biosciences Reports First Quarter 2026 Financial Results
September 1, 2026 Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
August 10, 2026 Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
August 10, 2026 Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
July 28, 2026 Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
July 13, 2026 Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
July 10, 2026 Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling
July 7, 2026 Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
June 2, 2026 Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics
